Delivery Order SPE2DB20D2014-SPE2DB25FC69C
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CellCept 500 mg tablets (500-count units) valued at $14,887.62 under a firm fixed-price contract. The award, issued on September 25, 2025, with an ultimate completion date of September 26, 2025, represents a non-competitive delivery order executed without a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfilled this order from its Corporate Office location,...
- The Defense Logistics Agency awarded a $3,611.49 delivery order to AmerisourceBergen Drug Corp for CellCept 500 mg tablets (100-count) under a firm fixed-price contract. The award was issued on September 15, 2025, with an ultimate completion date of September 16, 2025, and represents a non-competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for CellCept 500 mg tablets (500-count packages) valued at $12,029.30 under a firm fixed-price contract type. This award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle running through December 2026. CellCept (mycophenolate mofetil) is an...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of CellCept 500 mg tablets (100-count units) with a ceiling value of $8,966.40. This firm fixed-price delivery order, with an ultimate completion date of July 15, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $12,986.33 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500 count) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed price, competitively awarded delivery order represents a single pharmaceutical product shipment with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for CellCept 500 mg tablets (100 count) valued at $1,283.84, with an award date of August 13, 2025, and ultimate completion by August 14, 2025. This firm fixed-price, non-set-aside delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of CellCept 500 mg tablets (100-count units) with a ceiling value of $5,074.60. This is a firm fixed-price delivery order under an indefinite delivery contract vehicle, with an ultimate completion date of November 10, 2025. The contract was competitively awarded without set-aside designation to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $13,249.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count units). The contract was competitively awarded without set-aside designation and is set for completion by September 16, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $8,717.35 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count) on September 10, 2025, with completion scheduled for September 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, which is also the location of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of CellCept 500 mg tablets (100-count packages) under a firm fixed-price contract valued at $4,349.15. This is a non-set-aside competitive award with an ultimate completion date of August 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC69CDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,014.65 to AmerisourceBergen Drug Corp for CellCept 500 mg tablets (500-count packages) on August 7, 2025, with a completion date of August 8, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime contract vehicle (SPE2DX) that extends through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order supports the Defense Logistics Agency's pharmaceutical supply chain for military and veteran healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to the Department of Defense and other federal healthcare programs through its DLA contract vehicle. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly used in military healthcare settings. The award reflects AmerisourceBergen's continued role as a critical pharmaceutical vendor within the DLA's global medical supply network, which serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 8/7/25 |